Clemens Unger - Concepedia

Author

Clemens Unger

University Medical Center Freiburg ORCID

Also Known As

C UNGER, C Unger, C. UNGER, C. Unger, Camille V. Unger, Christian Unger, Clemens UNGER, Clemens Unger, Juris Berzins, Unger C.

287

Publications

9.9K

Citations

H-Index

164

Concepts

All Affiliations

University Medical Center Freiburg Max Planck Institute for Biophysical Chemistry University of Freiburg Max Planck Society University of Göttingen

About

Clemens Unger is an author at University Medical Center Freiburg specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	92	5.6K
2	Natural Sciences	17	21	988
3	Health Sciences	10	10	965
4	Engineering	8	8	332
5	Nursing	1	1	12

Clemens Unger

135

Publications

8.9K

Citations

H-Index

Page 1

	Year	Citations
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease Andrea Kraft, Karin Weindel, Andreas Ochs, Cancer	1999	369
A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors K. Mross, Annette Frost, Simone Steinbild, Clinical Cancer Research	2012	329
Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Joachim Drevs, Ilse Hofmann, Harald Hugenschmidt, PubMed UrologyAngiogenesisOncologyPtk787/zk 222584Vessel Density	2000	309
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors Joachim Drevs, Patrizia Siegert, Michael Medinger, Journal of Clinical Oncology	2007	302
Probing the Cysteine-34 Position of Endogenous Serum Albumin with Thiol-Binding Doxorubicin Derivatives. Improved Efficacy of an Acid-Sensitive Doxorubicin Derivative with Specific Albumin-Binding Properties Compared to That of the Parent Compound Felix Kratz, André Warnecke, Karin Scheuermann, Journal of Medicinal Chemistry	2002	271
Nutrient Limitation Governs Staphylococcus aureus Metabolism and Niche Adaptation in the Human Nose Bernhard Krismer, Manuel Liebeke, Daniela Janek, PLoS Pathogens Microbial PathogensNiche AdaptationS. Aureus GrowthMedical MicrobiologyS. Aureus Carriers	2014	218
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Joachim Drevs, Ralph Müller-Driver, Christine Wittig, PubMed PathologyTumor BiologyAngiogenesisOncologyReceptor Tyrosine Kinase	2002	204
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice A. Kuhlencord, T. Maniera, H. Eibl, Antimicrobial Agents and Chemotherapy Parasitic DiseaseMedicinal ChemistryLeishmania DonovaniAntiparasitic AgentLeishmania Infantum	1992	198
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Ahmed M. Mansour, Joachim Drevs, N. Esser, PubMed ImmunologyMalignant MelanomaMatrix Metalloproteinase 2Tumor BiologyAnti-cancer Agent	2003	197
Tumor necrosis factor induces rapid production of 1'2'diacylglycerol by a phosphatidylcholine-specific phospholipase C. Stefan Schütze, Dinko Berkovic, O Tomsing, The Journal of Experimental Medicine ApoptosisImmunologyPathologyCell DeathPhosphatidylcholine-specific Phospholipase C	1991	186

Page 1